Investigational Drug Details
| Drug ID: | D455 |
| Drug Name: | Desvenlafaxine |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB06700 |
| DrugBank Description: | Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) class[Label]. Desvenlafaxine may be used to treat major depressive disorder[Label]. It is formulated as an extended release tablet[Label]. Desvenlafaxine was approved by the FDA in 2008[L6016]. |
| PubChem ID: | 125017 |
| CasNo: | 93413-62-8 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1 |
| Structure: |
|
| InChiKey: | KYYIDSXMWOZKMP-UHFFFAOYSA-N |
| Molecular Weight: | 263.3752 |
| DrugBank Targets: | Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; Sodium-dependent dopamine transporter |
| DrugBank MoA: | Desvenlafaxine, the active metabolite of venlafaxine, is a selective serotonin and norepinephrine reuptake inhibitor[A6990,A6991,Label]. Desvenlafaxine inhibits neurotransmitter reuptake in serotonin, norepinephrine, and dopamine transporters[A6991]. Desvenlafaxine inhibits serotonin transporters with 10 times the affinity of norepinephrine transporters, and dopamine transporters with the lowest affinity[A6991]. In vitro, desvenlafaxine has no inhibition of monoamine oxidase, and almost no affinity for muscarinic, cholinergic, H1-histaminergic, and alpha1-adrenergic receptors[A6991]. |
| DrugBank Pharmacology: | Desvenlafaxine is a selective serotonin and norepinephrine reuptake inhibitor[A6990,A6991,Label]. It lacks significant activity on muscarinic-cholinergic, H<sub>1</sub>-histaminergic, or α<sub>1</sub>-adrenergic receptors <i>in vitro</i>. Desvenlafaxine does not appear to exert activity against calcium, chloride, potassium and sodium ion channels and also lacks monoamine oxidase (MAO) inhibitory activity[A6991]. It was also shown to lack significant activity again the cardiac potassium channel, hERG, <i>in vitro</i>[A36975]. Compared to other SNRIs, desvenlafaxine undergoes simple metabolism, has a low risk of drug-drug interactions and does not have to be extensively titrated to reach a therapeutic dose[Label]. |
| DrugBank Indication: | Desvenlafaxine is indicated for the treatment of major depressive disorder in adults[A6990,A6991,Label]. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|